

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Xuanzhu Biopharmaceutical Co., Ltd.

軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

DATE OF BOARD MEETING

The board (the “**Board**”) of directors (the “**Directors**”) of Xuanzhu Biopharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that a meeting of the Board will be held on Monday, March 30, 2026 for the purpose of, among other matters, considering and approving the annual results of the Group for the year ended December 31, 2025 and its publication, and considering the recommendation on payment of a final dividend, if any.

By order of the Board

Xuanzhu Biopharmaceutical Co., Ltd.

Ms. Xu Yanjun

Chairperson of the Board and executive Director

Hong Kong, March 16, 2026

As of the date of this announcement, the Board comprises (i) Ms. Xu Yanjun, Dr. Li Jia Kui and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; and (iii) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.